Concerns on Using Polysorbate 80 in Vaccines

Poly-SOR-bate 80 (polyoxyethylene sorbitan monooleate or Tween 80) is an amber-colored, slightly bitter tasting liquid used primarily as an emulsifier in many food products, cosmetics, vitamins, medicines and …vaccines.

There are some concerns with the use of Polysorbate 80 in vaccine administration. Here are a few:

MSDS

According to the Material Safety Data Sheet (MSDS) for PolySorbate 80 there is no information available regarding carcinogenic, mutagenic, teratogenic, or developmental toxicity effects. [1]

Important to note: the lack of information means that the studies have not been performed or have been inconclusive.

The MSDS toxicity information addresses ingestion and inhalation only. It does not address injection.

Here is a list of vaccines that contain Polysorbate 80 [2]
DTaP (Infantix)
DTaP (Tripedia)
DTaP (Kinrix)
DTaP-HepB-IPV (Pediatrix)
DTaP-IPV/Hib (Pentacel)
HPV (Gardasil)
Influenza (Fluarix)
Influenza (Flulaval)
Pneumococcal (Prevnar 13)
Rotavirus (RotaTeq)
Tdap (Boostrix)


Taken directly from the MSDS (last updated NOV 2010):


"Special Remarks on Chronic Effects on Humans:
May cause adverse reproductive effects based on animal test data. No human data found. May cause cancer based on animal test data. No human data found. May affect genetic material (mutagenic)"[1]



Immunocontraceptive

Here’s a strange one -

A patent for a vaccine that would decrease the ability for fertility in animals (which can be found here -submitted by the University

of Georgia Research Foundation) “preferably includes Tween 80 (Polysobate 80)”. [3]

The patent immediately goes on to site the book “The Theory and Practical Application of Adjuvants” after declaring Tween 80 as a preferable ingredient. This book lists the benefits and pitfalls associated with the use of different adjuvants. Studies include such problems as isolation, adverse reactions and practical applications.[3][4]

At least there is a practical application for it - decreasing fertility?!  


Permeability of the Blood Brain Barrier

The blood-brain barrier (BBB) is a paradox. On one hand, it protects the brain from that would otherwise be a constant systemic barrage of noxious substances. On the other hand, it prevents, in large measure, the delivery of therapeutic agents to patients with brain tumors. [5]

That is why Polysorbate 80 is used in pharmacology to assist in the delivery of certain drugs or chemotherapeutic agents across the blood brain barrier. Nanoparticles are coated in polysorabate 80 and without the use of this type of nanoparticle, the drugs would not be able to cross the barrier and yield effect. [6]

You may think this is a strech. What does nanoparticles coated in polysobate 80 have to do with polysorbate 80 in vaccines? Surely the amount of polysorbate used and the mechanism is different. Unfortunately, it it known that polysorbate 80 causes BBB disturbance at intrevenous systemic doses as low as 3 mg. [6]


I encourage you to learn, read, research, and talk about wellness. Take responsibility for your choices and actions by understanding and making decisions with intent.



This post reflects the research and concern that I have about vaccination.  It doesn’t represent my opinion of people who choose to vaccinate.  Please know that, while my family has made this decision, we respect the right of all parents to choose to vaccinate if they feel this is best for their child.  I don’t have all the answers.  Most of us don’t.  We’re all in the same boat in that we need to make the best decision we can with the information we have.  And, ultimately, I believe that the Divine is in control – what is meant to be will prevail, no matter our decision.



References:

[1] Material Safety Data Sheet (MSDS) for PolySorbate 80 (http://www.sciencelab.com/msds.php?msdsId=9926645)

[2] CDC – Vaccine Excipient & Media Summary (http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf)

[3] ‘Fertility Impairing Vaccine And Methods of Use'

This application claims the benefit of U. S. Provisional Application No. 60/070,375, filed January 2,1998, U. S. Provisional Application No. 60/071,406, filed January 15,1998

[4] Duncan E S Stewart-Tull. The Theory and Practical Application of Adjuvants. 1994 (http://www.lavoisier.fr/livre/notice.asp?id=OKLWR6AARLOOWI)

[5] Robert Quencer & Edward Neuwelt. Advances in the Understanding of the Blood Brain Barrier in Neuro-Oncology. AJNR. 2002 Vol 23: 1807-1810

[6] J Kreuter. Nanoparticles and micorparticles for drug and vaccine delivery. Journal of Anatomy. Dec 1996; 189 (503-505)